Zacks: Analysts Anticipate Senseonics Holdings, Inc. (NYSE:SENS) Will Announce Quarterly Sales of $2.14 Million

Equities research analysts expect Senseonics Holdings, Inc. (NYSE:SENSGet Rating) to announce sales of $2.14 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Senseonics’ earnings, with the highest sales estimate coming in at $3.00 million and the lowest estimate coming in at $1.40 million. Senseonics posted sales of $2.85 million in the same quarter last year, which suggests a negative year over year growth rate of 24.9%. The company is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Senseonics will report full year sales of $15.55 million for the current financial year, with estimates ranging from $14.00 million to $17.44 million. For the next year, analysts expect that the company will post sales of $30.00 million, with estimates ranging from $22.00 million to $36.09 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Senseonics.

Separately, StockNews.com raised Senseonics to a “sell” rating in a research note on Wednesday, March 30th.

NYSE:SENS opened at $1.55 on Friday. The firm has a market capitalization of $718.06 million, a PE ratio of -1.87 and a beta of 0.59. Senseonics has a twelve month low of $1.40 and a twelve month high of $4.58.

About Senseonics (Get Rating)

Senseonics Holdings, Inc, a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months.

Featured Articles

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.